Citations

Clear

3314 citation(s) found for "Do, Alexander".

Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Noseworthy, Peter A. , Branda, Megan E. , Kunneman, Marleen , Hargraves, Ian , Sivly, Angela , Brito, Juan P. , Burnett, Bruce , Zeballos‐Palacios, Claudia , Suzuki, Takeki , Lee, Alexander T., Gorr, Haeshik, McCarthy, Sarah , Shah, Nilay D. , Fleming, Kirsten, Haffke, Alexander, Muegge, Jule , Poplau, Sara , Simpson, Benjamin , Vang, Miamoua, Wambua, Mike , Anderson, Joel, Behnken, Emma , Cabalka, Renee, Ferrara, Michael J. , Giblon, Rachel , Inselman, Jonathan , Olive, Marc, Organick, Paige, Spencer‐Bonilla, Gabriela , Stier, Amy, Thota, Anjali, Ting, Henry H. , Vanmeter, Derek , Nicollet, Park, Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , McCarthy, Sarah R. , Hargraves, Ian G, Sivly, Angela L, Suzuki, Takeki , Jackson, Elizabeth A , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Branda, Megan , Brito, Juan P , Burnett, Bruce, Linzer, Mark , Jackson, Elizabeth A. , Hess, Erik P. , Montori, Víctor M. , Fleming, Kirsten, Burnett, Bruce, Hamilton, James, Simpson, Benjamin, Bellolio, Fernanda , Fleming, Kirsten, LeBlanc, Annie , Lee, Alexander , Burnett, Bruce, Harvey, Lisa Anne , Stephens, Shannon W. , Hamilton, James, Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D. , McCarthy, Sarah R.

Mayo Clinic

Journal of the American Heart Association | January 13, 2022 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/jaha.121.023048 | PMID 35023356 Get It

Background Guidelines promote shared decision‐making (SDM) for anticoagulation in patients with atrial fibrillation. We recently showed that adding a within‐encounter SDM tool to usual care (UC) increases patient involvement in decision‐making and clinician satisfaction, without affecting encounter length. We aimed to estimate the extent to which use of an SDM tool changed adherence to the decided care plan and clinical safety end points. Methods and Results We conducted a multicenter, encounter‐level, randomized trial assessing the efficacy of UC with versus without an SDM conversation tool for use during the clinical encounter (Anticoagulation Choice) in patients with nonvalvular atrial fibrillation considering starting or reviewing anticoagulation treatment. We conducted a chart and pharmacy review, blinded to randomization status, at 10 months after enrollment to assess primary adherence (proportion of patients who were prescribed an anticoagulant who filled their first prescription) and secondary adherence (estimated using the proportion of days for which treatment was supplied and filled for direct oral anticoagulant, and as time in therapeutic range for warfarin). We also noted any strokes, transient ischemic attacks, major bleeding, or deaths as safety end points. We enrolled 922 evaluable patient encounters (Anticoagulation Choice=463, and UC=459), of which 814 (88%) had pharmacy and clinical follow‐up. We found no differences between arms in either primary adherence (78% of patients in the SDM arm filled their first prescription versus 81% in UC arm) or secondary adherence to anticoagulation (percentage days covered of the direct oral anticoagulant was 74.1% in SDM versus 71.6% in UC; time in therapeutic range for warfarin was 66.6% in SDM versus 64.4% in UC). Safety outcomes, mostly bleeds, occurred in 13% of participants in the SDM arm and 14% in the UC arm. Conclusions In this large, randomized trial comparing UC with a tool to promote SDM against UC alone, we found no significant differences between arms in primary or secondary adherence to anticoagulation or in clinical safety outcomes. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: clinicaltrials.gov. Identifier: NCT02905032.
Sport-Related Concussion Preceding Adrenal Insufficiency and Hypopituitarism
Northam, Weston T. , Carneiro, Kevin A., Alexander, Andrew

Mayo Clinic

Current Sports Medicine Reports | January 12, 2022 | Volume: 21 | Issue: 1 | Pages: 15-17

10.1249/jsr.0000000000000926 | PMID 35018894 Get It

Abstract A 49-year-old woman with a history of daily inhaled corticosteroid use for asthma presented to a concussion clinic 7 wk after sport-related head injury with headache, visual blurring, dizziness, nausea, fatigue, polydipsia, and polyuria. Examination revealed difficulty with vestibulo-occulomotor testing due to nausea and visual straining. Cranial CT/MR imaging was unremarkable. Laboratory testing revealed critically low serum cortisol, hypernatremia, and urine studies suggesting diabetes insipidus. The patient was referred to the emergency department. Intravenous fluid resuscitation, corticosteroids, and desmopressin led to significant symptomatic relief. She was maintained on oral hydrocortisone after cosyntropin test revealed adrenal insufficiency. Her clinical picture suggested chronic subclinical adrenal suppression from inhaled corticosteroids, which was exacerbated by hypopituitarism possibly from concussion combined with diabetes insipidus. Adrenal insufficiency should be considered in athletes with history of corticosteroid use and endocrine-related symptoms after concussion, because this can create significant morbidity and can mimic traditional symptoms of concussion.
Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis
Perou, Charles M. , Hinoue4, Toshinori, Wheeler, Gregory , Kelly, Benjamin , Garrido-Castro, Ana C. , Cubas, Aguirre De, Rajkovic, Andrei, Karaesmen, Ezgi , Fan, Cheng, Creighton, Chad J. , Leraas, Kristen , Burns, Robyn, Coppens, Sara E. , Wheless, Amy, Rezk, Salma, Garrett, Amy, Foy, Kelly K. , Park, Ben, Krop, Ian E. , Anders, Carey K. , Rimawi, Mothaffar F. , Nanda, Rita , Storniolo, Anna Maria , Chandran, Uma , Davis, Michael J. , Ropelewski, Alexander J. , Liu, Minetta C. , Richardson, Andrea L. , Symmans, W. Fraser , Davidson, Nancy E. , King, Tari A. , Perou, Charles M , Rimawi, Mothaffar , Symmans, W Fraser , García‐Recio, Susana , Hinoue4, Toshinori, Pascual, Tomás , Xia, Youli , McClure, Marni B. , Smith, Markia A. , Fan, Cheng, Bowen, Jay , Parker, Joel S. , Shen, Hui , Gastier‐Foster, Julie M. , Lin, Nancy U. , Isaacs, Claudine , Marcom, Paul Kelly , Couch, Fergus J. , Silverstein, Jonathan C. , Hilsenbeck, Susan Galloway , Norton, Larry , Wolff, Antonio C. , Carey, Lisa A. , Lee, Adrian V. , Balko, Justin M. , Hoadley, Katherine A. , Laird, Peter W. , Mardis, Elaine R.

Mayo Clinic

No container title available | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1221704/v1 Get It

Abstract Patients with metastatic breast cancer (MBC) typically have short survival times and their successful treatment represents one of most challenging aspects of patient care. This poor prognostic behavior is in part due to molecular features including increased tumor cell clonal heterogeneity, multiple drug resistance mechanisms, and alterations of the tumor microenvironment. The AURORA US Metastasis Project was established with the goal to identify molecular features specifically associated with metastasis. We therefore collected and molecularly characterized specimens from 55 metastatic breast cancer (BC) patients representing 51 primary cancers and 102 metastases. The 153 unique tumors were assayed using RNAseq, tumor/germline DNA exomes and low pass whole genome sequencing, and global DNA methylation microarrays. We found intrinsic molecular subtype differences between primary tumors and their matched metastases to be rare in triple negative breast cancer (TNBC)/Basal-like subtype tumors. Conversely, tumor subtype changes were relatively frequent in estrogen receptor positive (ER+) cancers where ~30% of Luminal A cases switched to Luminal B or HER2-enriched (HER2E) subtypes. Clonal evolution studies identified changes in expression subtype coincident with DNA clonality shifts, especially involving HER2 amplification and/or the HER2E expression subtype. We further found evidence for ER-mediated downregulation of genes involved in cell-cell adhesion in metastases. Microenvironment differences varied according to tumor subtype where ER+/Luminal metastases had lower fibroblast and endothelial cell content, while TNBC/Basal-like metastases showed a dramatic decrease in B cells and T cells. In 17% of metastatic tumors, we identified DNA hypermethylation and/or focal DNA deletions near HLA-A that were associated with its’ significantly reduced expression, and with lower immune cell infiltrates. We also identified low immune cell features in brain and liver metastases when compared to other metastatic sites, even within the same patient. These findings have direct implications for the treatment of metastatic breast cancer patients with immune- and HER2-targeting therapies and suggest potential novel therapeutic avenues for the improvement of outcomes for some patients with MBC.
Abstract PO-197: Combined effect of a prostate cancer polygenic risk score and germline pathogenic variants in DNA damage repair genes on prostate cancer risk in men of African ancestry
Matejcic, Marco , Patel, Yesha , Lilyquist, Jenna , Xia, Lucy , Sheng, Xin , Lubmawa, Alexander, Watya, Stephen , Conti, David V. , Haiman, Christopher A. , Conti, David V , Hughley, Raymond W. , Darst, Burcu F. , Hart, Steven N. , Polley, Eric C. , Ingles, Sue A. , Wilkens, Lynne R. , Marchand, Loı̈c Le , Couch, Fergus J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-197-PO-197

10.1158/1538-7755.disp21-po-197 Get It

Abstract Introduction: Prostate Cancer (PCa) risk is influenced by both rare germline pathogenic variants (GPVs) in DNA damage repair genes and common variants as measured by polygenic risk scores (PRS) however, the combined effect of GPVs and PRS on PCa risk in men of African ancestry has not been investigated. Methods: We examined the combined effect of rare GPVs and PRS on PCa risk in 1,795 PCa cases and 1,424 controls of African ancestry men from the Multiethnic Cohort, the Los Angeles Study of Aggressive Prostate Cancer, and the Uganda Prostate Cancer Study. GPVs in 19 DNA genes were defined as clinically validated missense variants and variants that alter the protein sequence. The PRS was constructed as a weighted sum of 267 established PCa risk variants. The combined effect of the PRS and GPV status on PCa risk was evaluated using logistic regression models adjusting for age, study, and the first 10 principal components of ancestry to account for population stratification. Results: We identified 91 GPVs carried by 31 controls and 68 cases. Among GPV non-carriers, compared to those with average PRS (33.3-66.7%), odds ratios for PCa ranged from 0.56 (95% CI=0.45-0.70; P=1.2E-7) in low PRS men (0-33.3%) to 3.04 (95% CI=2.54-3.63; P=5.6E-35) in high PRS men (66.7-100%). Among GPV carriers, odds ratios for PCa ranged from 2.09 (95% CI=0.85-5.12; P=0.11) in low PRS men to 5.03 (95% CI=2.37-10.66; P=2.5E-5) in high PRS men, compared to GPV non-carriers with average PRS. Next, we restricted GPVs to ATM, BRCA2, PALB2, and NBN[BD2] (n=51 variants carried by 8 controls and 44 cases), which we previously reported as being the genes most strongly associated with advanced PCa in this population and study sample. Among GPV non-carriers, odds ratios for PCa ranged from 0.56 (95% CI=0.46-0.71; P=2.7E-7) in low PRS men to 5.03 (95% CI=0.85-5.12; P=0.11) in high PRS men, while among GPV carriers, odd ratios for PCa ranged from 2.08 (95% CI=0.58-7.49; P=0.26) in low PRS men to 18.06 (95% CI=4.24-76.84; P=9.0E-5) in high PRS men, compared to average PRS GPV non-carriers. When comparing aggressive cases to controls, considering the top four genes, GPV non-carrier odds ratios for PCa ranged from 0.52 (95% CI=0.40-0.70; P=6.2E-6) in low PRS men to 3.16 (95% CI=2.56-3.91; P=1.6E-26) in high PRS men, while among GPV carriers, odd ratios for PCa ranged from 2.97 (95% CI=073-12.16; P=0.13) in low PRS men to 23.58 (95% CI=5.39-103.20; P=2.7E-5) in high PRS men, compared to average PRS GPV non-carriers. Conclusion: We found that PCa risk in African ancestry men carrying GPVs in DNA damage repair and cancer predisposition genes, particularly ATM, BRCA2, PALB2, and NBN, varied depending on an individual's PRS. This implies that to comprehensively assess genetic risk of PCa, it is important to consider both rare and common variants. These findings could have implications for risk stratification in this high-risk population and emphasize the need for larger genetic studies of PCa in African ancestry men to identify and characterize genetic risk factors in this population. Citation Format: Raymond W. Hughley, Burcu F. Darst, Marco Matejcic, Yesha Patel, Jenna Lilyquist, Steven N. Hart, Eric C. Polley, Lucy Xia, Xin Sheng, Alexander Lubmawa, Sue A. Ingles, Lynne Wilkens, Loïc L. Marchand, Stephen Watya, Fergus J. Couch, David V. Conti, Christopher A. Haiman. Combined effect of a prostate cancer polygenic risk score and germline pathogenic variants in DNA damage repair genes on prostate cancer risk in men of African ancestry [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-197.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
Mascarenhas, John , Kosiorek, Heidi E., Prchal, Josef T. , Rambaldi, Alessandro, Berenzon, Dmitriy, Yacoub, Abdulraheem , Harrison, Claire N., McMullin, Mary Frances , Vannucchi, Alessandro M. , Ewing, Joanne, O'Connell, Casey L., Mead, Adam J. , Winton, Elliott F., Leibowitz, D , Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Sandy, Lonette, Salama, Mohamad E., Najfeld, Vesna, Tripodi, Joseph , Farnoud, Noushin , Penson, Alexander , Weinberg, Rona Singer , Barbui, Tiziano , Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Dueck, Amylou C. , Hoffman, Ronald, Rambaldi, Alessandro , Najfeld, Vesna , Kiladjian, Jean-Jacques , Mead, Adam J , Leibowitz, David S , De Stefano, Valerio , Levine, Max F , Arango Ossa, Juan E , McGovern, Erin , Tripodi, Joseph , Farnoud, Noushin , Penson, Alexander V , Weinberg, Rona Singer , Price, Leah , Goldberg, Judith D , Barbui, Tiziano , Dueck, A. C. , Vannucchi, Alessandro M , Mascarenhas, John , Rambaldi, Alessandro , McMullin, Mary Frances , Najfeld, Vesna , Kosiorek, Heidi E., Prchal, Josef T. , Berenzon, Dmitriy, Yacoub, Abdulraheem , Harrison, Claire N., Ewing, Joanne, O'Connell, Casey L., Winton, Elliott F., Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Sandy, Lonette, Salama, Mohamad E., Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Hoffman, Ronald

Mayo Clinic

Blood | January 10, 2022 | Volume: 139 | Issue: 19 | Pages: 2931-2941

10.1182/blood.2021012743 | PMID 35007321 Get It

Abstract The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-α (PEG) in treatment-naïve, high-risk patients with ET/PV. The primary endpoint was complete response (CR) rate at 12 months. A total of 168 patients were treated for a median of 81.0 weeks. CR for HU was 37% and 35% for PEG (P = .80) at 12 months. At 24 to 36 months, CR was 20% to 17% for HU and 29% to 33% for PEG. PEG led to a greater reduction in JAK2V617F at 24 months, but histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%). At 12 months of treatment, there was no significant difference in CR rates between HU and PEG. This study indicates that PEG and HU are both effective treatments for PV and ET. With longer treatment, PEG was more effective in normalizing blood counts and reducing driver mutation burden, whereas HU produced more histopathologic responses. Despite these differences, both agents did not differ in limiting thrombotic events and disease progression in high-risk patients with ET/PV. This trial was registered at www.clinicaltrials.gov as #NCT01259856.
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study
Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Schulte, Claudia , Grover, Sandeep , Mohamed, Océane, Portugal, Berta, May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Mellick, George D., Zimprich, Alexander, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Koks, Sulev, Taba, Pille, Lesage, Suzanne, Brice, Alexis, Chartier‐Harlin, Marie‐Christine, Brockmann, Kathrin , Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Straniero, Letizia, Zecchinelli, Anna, Pezzoli, Gianni, Brighina, Laura, Ferrarese, Carlo, Annesi, Grazia, Quattrone, Andrea, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Toft, Mathias , Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Bardien, Soraya , Carr, Jonathan, Tolosa, Eduardo, Ezquerra, Mario , Pastor, Pau, Diez‐Fairen, Monica, Wirdefeldt, Karin, Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Puschmann, Andreas, Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J., Krüger, Rejko, Gasser, Thomas, Sharma, Manu , Elbaz, Alexis , Gasser, Thomas , Hattori, Nobutaka , Chartier‐Harlin, Marie‐Christine , Puschmann, Andreas , Guedes, Leonor Correia , Zimprich, Alexander , Clarke, Carl E , Mellick, George D. , Morrison, Karen , Krüger, Rejko , Ferrarese, Carlo , Kim, Yun Joong , Pezzoli, Gianni , Pástor, Pau , Ferreira, Joaquim J. , Portugal, Berta , Straniero, Letizia , Quattrone, Andrea , Matsuo, Hirotaka , Kawamura, Yusuke , Ran, Caroline , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Bardien, Soraya , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Schulte, Claudia , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Mohamed, Océane, Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Taba, Pille, Lesage, Suzanne, Brice, Alexis, Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Zecchinelli, Anna, Brighina, Laura, Annesi, Grazia, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Carr, Jonathan, Tolosa, Eduardo, Diez‐Fairen, Monica, Wirdefeldt, Karin , Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J.

Mayo Clinic

Movement Disorders | January 8, 2022 | Volume: 37 | Issue: 4 | Pages: 857-864

10.1002/mds.28902 | PMID 34997937 Get It

Abstract Background Previous prospective studies highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men. It is unclear whether this association is causal or explained by reverse causation or confounding. Objective The aim is to examine the association between genetically predicted dairy intake and PD using two‐sample Mendelian randomization (MR). Methods We genotyped a well‐established instrumental variable for dairy intake located in the lactase gene (rs4988235) within the Courage‐PD consortium (23 studies; 9823 patients and 8376 controls of European ancestry). Results Based on a dominant model, there was an association between genetic predisposition toward higher dairy intake and PD (odds ratio [OR] per one serving per day = 1.70, 95% confidence interval = 1.12–2.60, P = 0.013) that was restricted to men (OR = 2.50 [1.37–4.56], P = 0.003; P ‐difference with women = 0.029). Conclusions Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society
Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)
Cheng, En , Ou, Fang‐Shu , Ma, Chao , Spiegelman, Donna , Zhang, Sui , Zhou, Xin , Bainter, Tiffany M., Niedzwiecki, Donna , Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Giovannucci, Edward L. , Blarigan, Erin L. Van , Ng, Kimmie , Gross, Cary P. , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Saltz, Leonard , Niedzwiecki, Donna , Benson, Al , Kindler, Hedy , Giovannucci, Edward L , Van Blarigan, Erin L , Brown, Justin C , Ng, Kimmie , Fuchs, Charles S , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Saltz, Leonard B. , Mayer, Robert J. , Brown, Justin C. , Cheng, En

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 7 | Pages: 740-751

10.1200/jco.21.01784 | PMID 34995084 Get It

PURPOSECurrent tools in predicting survival outcomes for patients with colon cancer predominantly rely on clinical and pathologic characteristics, but increasing evidence suggests that diet and lifestyle habits are associated with patient outcomes and should be considered to enhance model accuracy.METHODSUsing an adjuvant chemotherapy trial for stage III colon cancer (CALGB 89803), we developed prediction models of disease-free survival (DFS) and overall survival by additionally incorporating self-reported nine diet and lifestyle factors. Both models were assessed by multivariable Cox proportional hazards regression and externally validated using another trial for stage III colon cancer (CALGB/SWOG 80702), and visual nomograms of prediction models were constructed accordingly. We also proposed three hypothetical scenarios for patients with (1) good-risk, (2) average-risk, and (3) poor-risk clinical and pathologic features, and estimated their predictive survival by considering clinical and pathologic features with or without adding self-reported diet and lifestyle factors.RESULTSAmong 1,024 patients (median age 60.0 years, 43.8% female), we observed 394 DFS events and 311 deaths after median follow-up of 7.3 years. Adding self-reported diet and lifestyle factors to clinical and pathologic characteristics meaningfully improved performance of prediction models (c-index from 0.64 [95% CI, 0.62 to 0.67] to 0.69 [95% CI, 0.67 to 0.72] for DFS, and from 0.67 [95% CI, 0.64 to 0.70] to 0.71 [95% CI, 0.69 to 0.75] for overall survival). External validation also indicated good performance of discrimination and calibration. Adding most self-reported favorable diet and lifestyle exposures to multivariate modeling improved 5-year DFS of all patients and by 6.3% for good-risk, 21.4% for average-risk, and 42.6% for poor-risk clinical and pathologic features.CONCLUSIONDiet and lifestyle factors further inform current recurrence and survival prediction models for patients with stage III colon cancer.
VP8: Immune Response and Revascularization of Acellular Nerve Allografts Following Mesenchymal Stem Cell Seeding and Surgical Angiogenesis
Saffari, Tiam M. , Johnson, Aaron J. , Bedar, Meiwand , Johnson, Aaron J. , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 9-10

10.1097/01.gox.0000817712.55742.df Get It

VP7: In Vitro Comparison of Dynamic Seeding Versus Microinjection of Mesenchymal Stem Cells for Acellular Nerve Allograft
Bedar, Meiwand , Jerez, Sofía , Pulos, Nicholas , Wijnen, André J. van , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 9-9

10.1097/01.gox.0000817708.46386.37 Get It

VP1: Combined Local Delivery of Tacrolimus and Stem Cells in Fibrin Gel is a Viable Potential Treatment for Enhancing Peripheral Nerve Regeneration
Saffari, Tiam M. , Zuo, Kevin J. , Chan, K., Saffari, Sara , Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 5, 2022 | Volume: 10 | Issue: 1S | Pages: 12-13

10.1097/01.gox.0000817736.46737.16 Get It